A5113247536- Advanced Breast Cancer Therapies
- Male Breast Health Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Health Literacy and Information Accessibility
- Peptidase Inhibition and Analysis
- Ear and Head Tumors
- Neuroblastoma Research and Treatments
- Breast Cancer Treatment Studies
- Metabolism, Diabetes, and Cancer
- Neuroendocrine Tumor Research Advances
- Patient-Provider Communication in Healthcare
- Cardiac tumors and thrombi
- Chronic Lymphocytic Leukemia Research
- Cancer-related cognitive impairment studies
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
- Chemotherapy-related skin toxicity
Izmir Tepecik Eğitim ve Araştırma Hastanesi
2024
Ege University
2022-2023
This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines treatment in patients with metastatic neuroendocrine tumors (NETs).
(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness safety of trabectedin. (2) Methods: A retrospective multicenter conducted on patients who were treated with trabectedin for metastatic at ten tertiary oncology centers between 2015 2023. The objective response rate (ORR), disease control (DCR), time...
Abstract Purpose: Cancer is a global health problem that threatens lives worldwide. Awareness of cancer diagnosis varies over time. It differs according to the attitudes societies, and there are not enough studies on this subject in Turkey, Eurasian country. Methods: Between January 1, 2018 March 31, 2018, 159 newly diagnosed patients who were admitted DEÜTF Medical Oncology Outpatient Clinic included study. In order evaluate level knowledge awareness about their diseases, questionnaire...
Epidermal growth factor receptor mutations are the second most common oncogenic driver event in non-small cell lung cancer. We aimed to compare first generation erlotinib treatment with afatinib patients non- small cancer epidermal exon 21 L861Q mutation.Progression-free survival and overall of 30 treated erlo- tinib or due single positivity were compared retrospectively. The number included first, second, third line was 15 (50.0%), 11 (36.7%), 4 (13.3%), respectively.There 23 arm 7 arm....